Envestnet Asset Management Inc. raised its holdings in shares of Doximity, Inc. (NASDAQ:DOCS – Get Rating) by 9.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,669 shares of the company’s stock after purchasing an additional 9,433 shares during the period. Envestnet Asset Management Inc. owned 0.06% of Doximity worth $3,344,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Janney Montgomery Scott LLC bought a new position in Doximity during the 2nd quarter valued at approximately $576,000. Yarbrough Capital LLC purchased a new position in shares of Doximity in the 3rd quarter worth $259,000. Vestmark Advisory Solutions Inc. boosted its stake in shares of Doximity by 30.4% in the 3rd quarter. Vestmark Advisory Solutions Inc. now owns 13,255 shares of the company’s stock worth $401,000 after buying an additional 3,094 shares during the last quarter. Zeke Capital Advisors LLC boosted its stake in shares of Doximity by 20.2% in the 2nd quarter. Zeke Capital Advisors LLC now owns 36,365 shares of the company’s stock worth $1,266,000 after buying an additional 6,107 shares during the last quarter. Finally, Renaissance Capital LLC raised its holdings in Doximity by 488.1% in the 3rd quarter. Renaissance Capital LLC now owns 41,317 shares of the company’s stock worth $1,249,000 after purchasing an additional 34,291 shares during the period. Institutional investors own 52.48% of the company’s stock.
Analyst Upgrades and Downgrades
DOCS has been the topic of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 target price on shares of Doximity in a report on Friday, February 10th. JPMorgan Chase & Co. decreased their target price on Doximity from $60.00 to $30.00 and set an “underweight” rating on the stock in a report on Friday, February 17th. Canaccord Genuity Group decreased their target price on Doximity from $42.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, February 10th. Evercore ISI raised their price target on Doximity from $28.00 to $32.00 in a report on Friday, November 11th. Finally, Wells Fargo & Company decreased their price target on Doximity from $44.00 to $39.00 and set an “overweight” rating on the stock in a report on Friday, February 10th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Doximity presently has an average rating of “Hold” and an average target price of $40.50.
Doximity Stock Down 1.0 %
Insider Buying and Selling
In related news, CFO Anna Bryson sold 25,000 shares of the company’s stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the chief financial officer now owns 104,763 shares in the company, valued at approximately $4,190,520. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 45.21% of the company’s stock.
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
- Get a free copy of the StockNews.com research report on Doximity (DOCS)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.